These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35368622)

  • 1. Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
    Iheanacho CO; Eze UIH
    Futur J Pharm Sci; 2022; 8(1):20. PubMed ID: 35368622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review.
    Sharifian-Dorche M; Bahmanyar M; Sharifian-Dorche A; Mohammadi P; Nomovi M; Mowla A
    J Neurol Sci; 2021 Sep; 428():117607. PubMed ID: 34365148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
    van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
    J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines.
    Elberry MH; Abdelgawad HAH; Hamdallah A; Abdella WS; Ahmed AS; Ghaith HS; Negida A
    J Thromb Thrombolysis; 2022 May; 53(4):798-823. PubMed ID: 35157188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Procter TD; Ogasawara H; Spruin S; Wijayasri S; Abraham N; Blaser C; Hutchings K; Shaw A; Ogunnaike-Cooke S
    Vaccine; 2023 Nov; 41(46):6802-6809. PubMed ID: 37806804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
    Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
    Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
    BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study.
    Morciano C; Massari M; Cutillo M; Belleudi V; Trifirò G; Mores N; Sapigni E; Puccini A; Zanoni G; Zorzi M; Monaco G; Leoni O; Del Zotto S; Samez S; Mayer F; Marano G; Menniti Ippolito F; Da Cas R; Traversa G; Spila Alegiani S
    Drug Saf; 2024 Nov; 47(11):1157-1169. PubMed ID: 39068268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
    Mouta Nunes de Oliveira P; Mendes-de-Almeida DP; Bertollo Gomes Porto V; Crespo Cordeiro C; Vitiello Teixeira G; Saraiva Pedro R; Roberto Gomes Takey P; Kegele Lignani L; Reis Xavier J; Cardoso Doria da Gama V; Amorim Filho L; Emoingt Furtado B; Santa Maria A; Dahrug Barros T; Neves Waite Freitas L; Dos Santos Pereira T; Lima Abreu D; Bernardes Ramos M; Gabe C; Arnold D; William Smith J; Nazy I; Lourdes de Sousa Maia M;
    Vaccine; 2022 Aug; 40(33):4788-4795. PubMed ID: 35779962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
    See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR
    JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response.
    Franceschi AM; Petrover DR; McMahon TM; Libman RB; Giliberto L; Clouston SAP; Castillo M; Kirsch C
    Clin Imaging; 2022 Oct; 90():63-70. PubMed ID: 35926315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
    Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
    Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.
    Kanack AJ; Singh B; George G; Gundabolu K; Koepsell SA; Abou-Ismail MY; Moser KA; Smock KJ; Green D; Major A; Chan CW; Wool GD; Reding M; Ashrani AA; Bayas A; Grill DE; Padmanabhan A
    Am J Hematol; 2022 May; 97(5):519-526. PubMed ID: 35132672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.